Literature DB >> 9708574

Role of insulin-like growth factor-I in esophageal mucosal healing processes.

M T Tchorzewski1, F G Qureshi, M D Duncan, K L Duncan, N Saini, J W Harmon.   

Abstract

The current study examines the stimulation of healing processes and signal transduction that is mediated by insulin-like growth factor-I (IGF-I) in an ex vivo esophageal explant model when using tyrphostin inhibition of receptor tyrosine kinase. The explant model provides a 3-dimensional cellular environment of multiple interacting cells isolated from the neural and vascular supply. Tyrphostins previously characterized for their interactions with epithelial growth factor (EGF) receptor-associated protein tyrosine kinases were tested for their potential effects on IGF-I growth-promoting activity. Explants of rabbit esophagus were incubated in media with or without IGF-I. Tyrphostins 1, 23, 25, 46, 47, 51, and 63 were added. We assessed DNA synthesis by tritiated thymidine incorporation. Outgrowth from the edge of the primary mucosa of the explant was evaluated on histologic sections, and cell proliferation was confirmed with immunohistology. IGF-I increased the incorporation of tritiated thymidine by 50% to 100%. Tyrphostins 23 and 47 eliminated IGF-I-induced proliferation in a dose-dependent manner. Tyrphostins 25, 46, and 51--along with negative controls tyrphostin 1 and tyrphostin 63--were ineffective, inasmuch as IGF-I-stimulated growth remained unchanged in their presence. Proliferative activity demonstrated by PCNA staining was confined to new mucosa. Two of 5 tyrphostins originally developed as EGF receptor protein tyrosine kinase inhibitors were effective in inhibiting the actions of exogenous IGF-I. We conclude that IGF-I stimulation may play an important role in repair processes in the esophagus and that this stimulation can be inhibited by using specific tyrphostins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708574     DOI: 10.1016/s0022-2143(98)90008-7

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  4 in total

1.  The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma.

Authors:  Yasushi Adachi; Hirokazu Ohashi; Arisa Imsumran; Hiroyuki Yamamoto; Yasutaka Matsunaga; Hiroaki Taniguchi; Katsuhiko Nosho; Hiromu Suzuki; Yasushi Sasaki; Yoshiaki Arimura; David P Carbone; Kohzoh Imai; Yasuhisa Shinomura
Journal:  Tumour Biol       Date:  2013-09-13

Review 2.  Dietary factors and the risks of oesophageal adenocarcinoma and Barrett's oesophagus.

Authors:  Ai Kubo; Douglas A Corley; Christopher D Jensen; Rubinder Kaur
Journal:  Nutr Res Rev       Date:  2010-07-13       Impact factor: 7.800

3.  Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma.

Authors:  Tiehong Zhang; Hongchang Shen; Wei Dong; Xiao Qu; Qi Liu; Jiajun Du
Journal:  Sci Rep       Date:  2014-10-31       Impact factor: 4.379

4.  Insulin-like growth factor-1, IGF binding protein-3, and the risk of esophageal cancer in a nested case-control study.

Authors:  Yasushi Adachi; Masanori Nojima; Mitsuru Mori; Kentaro Yamashita; Hiro-O Yamano; Hiroshi Nakase; Takao Endo; Kenji Wakai; Kiyomi Sakata; Akiko Tamakoshi
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.